Association study between genetic variations in Axin2 gene and lung cancer risk in North Indian population: A multiple interaction analysis

Tumor Biology

Volumn 39, Issue 4, 2017, Pages

  Bahl, Charu ^a   Sharma, Siddharth ^a   Singh, Navneet ^b   Behera, Digamber ^b  

^a THAPAR UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Axin2; Lung cancer; single nucleotide polymorphism; Wnt pathway

Indexed keywords

AXIS INHIBITION PROTEIN 2; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; AXIN; AXIN2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENETIC VARIATION; GENOTYPE; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; INDIAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL LUNG CARCINOMA; TUMOR SUPPRESSOR GENE; AGED; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; INDIA; LUNG TUMOR; MIDDLE AGED; RISK;

ADULT; AGED; AXIN PROTEIN; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 85017482643     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317695533     Document Type: Article

References (39)

1. Yardy GW, Brewster SF., Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 2005; 1: 119–126.
2. Luo J, Chen J, Deng Z-L. Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 2007; 87: 97–103.
3. Akiyama T., Wnt/β-catenin signaling. Cytokine Growth Factor Rev 2000; 11: 273–282.
4. Stewart DJ., Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 2014; 106: 1–11.
5. Kikuchi A., Modulation of Wnt signalling by Axin and Axil. Cytokine Growth Factor Rev 1999; 10: 255–265.
6. Dong X, Seelan RS, Qian C. Genomic structure, chromosome mapping and expression analysis of the human AXIN2 gene. Cytogenet Cell Genet 2001; 28: 26–28.
7. Yang Y., Wnt signaling in development and disease. Cell Biosci 2012; 2: 1
8. Tetsu O, McCormick F., β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422–426.
9. Barker N, Clevers H., Mining the Wnt pathway for cancer therapeutics. Nature 2007; 5: 997–1015.
10. Polakis P., Wnt signalling and cancer. Genes Dev 2000; 14: 1837–1851.
11. Winn RA, Bremnes RM, Bemis L. γ-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene 2002; 21: 7497–7506.
12. Mazieres J, He B, You L. Wnt signaling in lung cancer. Cancer Lett 2005; 222: 1–10.
13. Huang H, He X., Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 2008; 20: 119–125.
14. Davoodi B, Kh O, Heydari Nasrabadi M., Genetic polymorphism of the Axin2 gene in Wnt pathway in patients with ovarian cancer. J Ardabil Univ Med Sci 2015; 15: 220–227.
15. Phelan CM, Borg A, Cuny M. Consortium study on 1280 breast carcinoma; allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res 2000; 58: 1004–1012.
16. Gong J, Jiang Y, Hao N. Quantitative assessment of the association between AXIN2 rs2240308 polymorphism and cancer risk. Sci Rep 2015; 5: 1–7.
17. Tseng RC, Lin RK, Wen CK. Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis. Oncogene 2008; 27: 4488–4496.
18. Marshall AL, Christiani DC., Genetic susceptibility to lung cancer—light at the end of the tunnel?. Carcinogenesis 2013; 34: 487–502.
19. Wu Z, Sun Y, Tang S. AXIN2 rs2240308 polymorphism contributes to increased cancer risk: evidence based on a meta-analysis. Cancer Cell Int 2015; 15: 68.
20. Gunes EG, Pinarbasi E, Pinarbasi H. Strong association between lung cancer and the AXIN2 polymorphism. Mol Med Rep 2009; 2: 1029–1035.
21. Kanzaki H, Ouchida M, Hanafusa H., Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. Int J Mol Med 2006; 18: 279–284.
22. Mostowska A, Pawlik P, Sajdak S., An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population. Mol Diagn Ther 2014; 18: 85–91.
23. Liu D, Li L, Yang Y. The Axin2 rs2240308 polymorphism and susceptibility to lung cancer in a Chinese population. Tumor Biol 2014; 35: 10987–10991.
24. Ma C, Liu C, Huang P. Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer. Oncol Lett 2014; 8: 789–794.
25. Gunes EG, Pinarbasi E, Pinarbasi H., AXIN2 polymorphism and its association with astrocytoma in a Turkish population. Mol Med Rep 2010; 3: 705–709.
26. Sobti RC, Sharma S, Joshi A. Genetic polymorphism of the CYP1A1, CYP 2E1, GSTM1 & GSTT1 genes and lung cancer susceptibility in a north Indian population. Mol Cell Biochem 2004; 266: 1–9.
27. Páez D, Gerger A, Zhang W. Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence. Pharmacogenomics J 2014; 14: 142–150.
28. Shi YY, He L., SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97–98.
29. Ritchie MD, Motsinger AA., Multifactor dimensionality reduction for detecting gene–gene and gene–environment interactions in pharmacogenomics studies. Future Med 2005; 6: 823–834.
30. Srivastava A, Sharma KL, Srivastava N. Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy. PLoS One 2012; 7: e40162.
31. Rubinfeld B, Robbins P, El-Gamil M. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790–1792.
32. Aristizabal-Pachon AF, Carvalho TI, Humberto H. AXIN2 polymorphisms, the β-catenin destruction complex expression profile and breast cancer susceptibility. Asian Pac J Cancer P 2015; 16: 7277–7284.
33. Ikeda S, Kishida S, Yamamoto H. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of betacatenin. EMBO J 1998; 17: 1371–1384.
34. Willert K, Shibamoto S, Nusse R., Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev 1999; 13: 1768–1773.
35. Shen LX, Basilion JP, Stanton VP., Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci USA 1999; 96: 7871–7876.
36. Mostowska A, Biedziak B, Jagodzinski PP., Axis inhibition protein 2 (AXIN 2) polymorphisms may be a risk factor for selective tooth agenesis. J Hum Genet 2006; 51: 262–266.
37. Callahan N, Modesto A, Meira R. Axis inhibition Protein2 (AXIN2) and tooth agenesis. Arch Oral Biol 2009; 54: 45–49.
38. Sodhi KK, Bahl C, Singh N. Functional genetic variants in pre-miR-146a and 196a2 genes are associated with risk of lung cancer in North Indians. Future Oncol 2015; 11: 2159–2173.
39. Han S, Lv L, Wang X. Association of AXIN2 and MMP7 polymorphisms with non-small cell lung cancer in Chinese Han population. Int J Clin Exp Pathol 2016; 9: 2253–2258.